Package 0071-2418-19

{"route": ["ORAL"], "spl_id": "6afa95d3-162a-4fbb-ab47-561f4ee7771a", "openfda": {"nui": ["N0000175753", "N0000008486"], "unii": ["5SEH9X1D1D"], "rxcui": ["251322", "755357"], "spl_set_id": ["7bf3e616-45e8-4469-a75d-4d824ce951ea"], "pharm_class_pe": ["Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "pharm_class_epc": ["Anti-epileptic Agent [EPC]"], "manufacturer_name": ["Parke-Davis Div of Pfizer Inc"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1 BOTTLE, PLASTIC in 1 CARTON (0071-2418-19)  / 474 mL in 1 BOTTLE, PLASTIC", "package_ndc": "0071-2418-19", "marketing_start_date": "20220601"}], "brand_name": "Zarontin", "product_id": "0071-2418_6afa95d3-162a-4fbb-ab47-561f4ee7771a", "dosage_form": "SOLUTION", "pharm_class": ["Anti-epileptic Agent [EPC]", "Decreased Central Nervous System Disorganized Electrical Activity [PE]"], "product_ndc": "0071-2418", "generic_name": "Ethosuximide", "labeler_name": "Parke-Davis Div of Pfizer Inc", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Zarontin", "active_ingredients": [{"name": "ETHOSUXIMIDE", "strength": "250 mg/5mL"}], "application_number": "ANDA080258", "marketing_category": "ANDA", "marketing_start_date": "20200310", "listing_expiration_date": "20261231"}